Healthy Volunteers Clinical Trial
Official title:
Study of the Effects of Commercial Air Travel on Pulmonary Artery Pressure in Healthy Passengers and in a Patient With Chuvash Polycythaemia
The study hypothesis is that commercial air travel causes an increase in the blood pressure in the lungs (pulmonary artery pressure) that can be clinically relevant. Portable echocardiography (heart ultrasound) now offers a non-invasive means of studying this in-flight.
In a commercial airliner flying at high altitude, the reduced cabin air pressure means that
all passengers are exposed to slightly lowered oxygen levels ('hypoxia') equivalent to an
altitude of approximately 5,000 to 8,000 ft. Although mild, this hypoxia is sufficient to
stimulate some of the body's protective responses (eg changes in breathing and in hormonal
secretion) and can be dangerous for passengers with heart or lung disease, who must breathe
supplementary oxygen in-flight or may even be prohibited from flying because of the risks of
hypoxia.
It is well known that severe hypoxia results in constriction of blood vessels in the lungs
(a phenomenon called hypoxic pulmonary vasoconstriction), which in turn causes an increase
in the blood pressure in the lungs ('pulmonary arterial pressure'). Unlike other
physiological responses to hypoxia, this is often harmful and frequently leads to pulmonary
hypertension and right heart failure (eg in some lung diseases and at high altitude). Even a
modest increase in pulmonary arterial pressure could be clinically important in some airline
passengers with heart/lung disease, as it may exacerbate their condition. However, it is not
known whether the mild hypoxia experienced in an aircraft cabin is able to cause an increase
in pulmonary artery pressure. Limited evidence suggests that it might - for example, there
have been reports of passengers acutely developing new right heart failure in-flight, and
data from animal studies also support this possibility.
This study aims to establish the effect of mild aircraft cabin hypoxia on pulmonary arterial
pressure in healthy passengers and also in a patient with Chuvash polycythaemia. In this
rare genetic disease, cellular responses to hypoxia are 'switched on' to some extent even
during normoxia, causing increased red blood cell production. Affected individuals usually
present with symptoms of polycythaemia in early adulthood and are typically asymptomatic
following treatment with therapeutic venesection. Importantly, affected individuals have
exaggerated acute hypoxic pulmonary vasoconstriction which may place them at risk of
pulmonary hypertensive responses during air travel.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |